Pyruvate Carboxylase Is Critical for Non-Small-Cell Lung Cancer Proliferation by Sellers, Katherine et al.
University of Kentucky
UKnowledge
Toxicology and Cancer Biology Faculty
Publications Toxicology and Cancer Biology
1-20-2015
Pyruvate Carboxylase Is Critical for Non-Small-
Cell Lung Cancer Proliferation
Katherine Sellers
University of Louisville
Matthew P. Fox
University of Louisville
Michael Bousamra II
University of Louisville
Stephen P. Slone
University of Louisville
Richard M. Higashi
University of Kentucky, rick.higashi@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/toxicology_facpub
Part of the Medical Toxicology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in
Toxicology and Cancer Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Sellers, Katherine; Fox, Matthew P.; Bousamra, Michael II; Slone, Stephen P.; Higashi, Richard M.; Miller, Donald M.; Wang, Yali; Yan,
Jun; Yuneva, Mariia O.; Deshpande, Rahul; Lane, Andrew N.; and Fan, Teresa W-M, "Pyruvate Carboxylase Is Critical for Non-Small-
Cell Lung Cancer Proliferation" (2015). Toxicology and Cancer Biology Faculty Publications. 27.
https://uknowledge.uky.edu/toxicology_facpub/27
Authors
Katherine Sellers, Matthew P. Fox, Michael Bousamra II, Stephen P. Slone, Richard M. Higashi, Donald M.
Miller, Yali Wang, Jun Yan, Mariia O. Yuneva, Rahul Deshpande, Andrew N. Lane, and Teresa W-M Fan
Pyruvate Carboxylase Is Critical for Non-Small-Cell Lung Cancer Proliferation
Notes/Citation Information
Published in The Journal of Clinical Investigation, v. 125, no. 2, p. 687-698.
Copyright © 2015, The American Society for Clinical Investigation.
Authors retain rights to present the work without prior permission in original, revised, adapted, or derivative
form, provided that all such use is for personal or nonprofit (and noncommercial)benefit, is consistent with
any employment agreement, and references the original publication citation.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1172/JCI72873
This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/27
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1jci.org
Introduction
Accelerated glycolysis under aerobic conditions (the “Warburg 
effect”) has been a hallmark of cancer for many decades (1). It is 
now recognized that cancer cells must undergo many other met-
abolic reprogrammings (2) to meet the increased anabolic and 
energetic demands of proliferation (3, 4). It is also becoming clear 
that different cancer types may utilize a variety of metabolic adap-
tations that are context dependent (5–11), commensurate with 
the notion that altered metabolism is a hallmark of cancer (12). 
Enhanced glucose uptake and aerobic glycolysis generates both 
energy (i.e., ATP) and molecular precursors for the biosynthesis 
of complex carbohydrates, sugar nucleotides, lipids, proteins, and 
nucleic acids (3, 13, 14). However, increased glycolysis alone is 
insufficient to meet the total metabolic demands of proliferating 
cancer cells. The Krebs cycle is also a source of energy via the oxi-
dation of pyruvate, fatty acids (15), and amino acids such as glu-
tamine (10, 16, 17). Moreover, several Krebs cycle intermediates 
are essential for anabolic and glutathione metabolism, including 
citrate, oxaloacetate, and α-ketoglutarate (Figure 1A).
Continued functioning of the Krebs cycle requires the replen-
ishment of intermediates that are diverted for anabolic uses or 
glutathione synthesis. This replenishment process, or anaplero-
sis, is accomplished via 2 major pathways: glutaminolysis (deam-
idation of glutamine via glutaminase [GLS] plus transamination 
of glutamate to α-ketoglutarate) (18, 19) and carboxylation of 
pyruvate to oxaloacetate via ATP-dependent pyruvate carboxy-
lase (PC) (EC 6.4.1.1) (refs. 3, 20, 21, and Figure 1A). The relative 
importance of these pathways is likely to depend on the nature of 
the cancer and its specific metabolic adaptations, including those 
to the microenvironment (20, 22).
For example, glutaminolysis was shown to be activated in the 
glioma cell line SF188, while PC activity was absent (17), despite 
the high PC activity present in normal astrocytes (23, 24). How-
ever, SF188 cells use PC to compensate for GLS1 suppression or 
glutamine restriction (20), and PC, rather than GLS1, was shown 
to be the major anaplerotic input to the Krebs cycle in primary 
glioma xenografts in mice (22). It is also unclear as to the relative 
importance of PC and GLS1 in other cancer cell types or, most 
relevantly, in human tumor tissues in situ. Our preliminary evi-
dence from 5 non–small-cell lung cancer (NSCLC) patients indi-
cated that PC expression and activity are upregulated in cancerous 
(CA) compared with paired noncancerous (NC) lung tissues (21), 
although it was unclear whether PC activation applies to a larger 
NSCLC cohort or whether PC expression was associated with the 
cancer and/or stromal cells. Nor has the relationship between PC 
activation and glutaminase status been explored in human patient 
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the second turn of the Krebs cycle via 13C4-citrate, which is the 
condensation product of 13C2-acetyl CoA and 13C2-oxaloacetate 
(OAA). Since the 13C enrichment of the 13C4-citrate precursor was 
lower than that of the 13C3-Asp product (Supplemental Figure 1, 
B and C, and Figure 1D), it argues against a significant contri-
bution of this route to 13C3-Asp enrichment. We also measured 
PC activity by the fractional 13C enrichment of other markers, 
13C3-citrate, 13C5-citrate, and 13C3-malate, which were, respec-
tively, 27%, 88%, and 113% higher in CA lung tissues than in NC 
lung tissues (Figure 1D). We also observed that 13C3-citrate was 
5- to 6-fold higher in fractional enrichment than was 13C5-citrate 
for both CA and NC lungs. This could be attributed to the expect-
edly low 13C enrichment in pyruvate and thus acetyl CoA due 
to a large dilution of the 13C-glucose tracer in the human body, 
leading to a lower probability of condensation of 13C3-OAA with 
13C2-acetyl CoA than with unlabeled acetyl CoA to produce less 
13C5-citrate than 13C3-citrate. Moreover, the fractional enhance-
ment of 13C3-citrate in CA over NC lungs was less than that of 
13C5-citrate (Figure 1D). This could be a result of increased flux 
through the pyruvate dehydrogenase–initiated (PDH-initiated) 
Krebs cycle reactions in CA lung compared with that in NC lung, 
as evidenced by the elevated fraction of 13C2 isotopologs of Krebs 
cycle metabolites in CA versus NC lung (Supplemental Figure 
1B). This could in turn lead to a relatively higher enrichment of 
13C2-acetyl CoA and thus its product (13C5-citrate) of condensa-
tion with 13C3-OAA in CA lung compared with that in NC lung. 
Altogether, the significant increase in the fractional enrichment 
of these PC markers reflects increased PC activity (which we 
refer to herein) in the cancer tissue.
In addition to enhanced production of labeled PC markers, we 
observed a higher percentage of enrichment in the 13C2-isotopologs 
of Krebs cycle metabolites (citrate+2, glutamate+2, succinate+2, 
fumarate+2, malate+2, and aspartate+2 in Supplemental Figure 
1B) in NSCLC tumors than in NC lung tissue, which is indicative of 
enhanced glucose oxidation in the Krebs cycle via PDH.
Fresh tissue (Warburg) slices confirm enhanced PC and Krebs cycle 
activity in NSCLC. To further assess PC activity relative to GLS1 
activity in human lung tissues, thin (<1 mm thick) slices of paired 
CA and NC lung tissues freshly resected from 13 human NSCLC 
patients were cultured in 13C6-glucose or 13C5,15N2-glutamine for 24 
hours. These tissues maintain biochemical activity and histologi-
cal integrity for at least 24 hours under culture conditions (Figure 
2A, Supplemental Figure 2, A and B, and ref. 26). When the tissues 
were incubated with 13C6-glucose, CA slices showed a significantly 
greater percentage of enrichment in glycolytic 13C3-lactate (3 in 
Figure 2B) than did the NC slices, indicative of the Warburg effect. 
In addition, the CA tissues had significantly higher fractions of 
13C4-, 13C5-, and 13C6-citrate (4, 5, and 6 of citrate, respectively, in 
Figure 2B) than did the NC tissues. These isotopologs require the 
combined action of PDH, PC, and multiple turns of the Krebs cycle 
(Figure 2C). Consistent with the labeled citrate data, the increase in 
the percentage of enrichment of 13C3-, 13C4-, and 13C5-glutamate (3, 
4, and 5 of glutamate, respectively, in Figure 2B) in the CA tissues 
indicates enhanced Krebs cycle and PC activity.
When tissue slices were incubated with 13C5,15N2-glutamine, 
13C5,15N1-glutamate (6 of glutamate in Supplemental Figure 2C) 
was produced in both CA and NC tissues, indicating active gluta-
studies. Moreover, the role of PC in cell survival and proliferation 
and whether glutaminolysis can compensate for this role under PC 
suppression in lung cancer cells is unknown.
Here, we have greatly extended our previous findings (21) in a 
larger cohort (n = 86) by assessing glutaminase 1 (GLS1) status and 
analyzing in detail the biochemical and phenotypic consequences 
of PC suppression in NSCLC. We found PC activity and protein 
expression levels to be, on average, respectively, 100% and 5- to 
10-fold higher in cancerous (CA) lung tissues than in paired NC 
lung tissues resected from NSCLC patients, whereas GLS1 expres-
sion showed no significant trend. We have also applied stable 
isotope–resolved metabolomic (SIRM) analysis to paired freshly 
resected CA and NC lung tissue slices in culture (analogous to the 
Warburg slices; ref. 25) using either [U-13C] glucose or [U-13C,15N] 
glutamine as tracers. This novel method provided information 
about tumor metabolic pathways and dynamics without the com-
plication of whole-body metabolism in vivo. We used immuno-
histochemical analysis to verify the specific localization of PC in 
cancer cells within the tumor tissue. We further determined the 
functional role of PC in NSCLC cell lines using shRNA, which 
showed that attenuation of PC activity inhibited cell proliferation, 
colony formation, and tumor growth in mouse xenografts, while 
compromising the cells’ ability to quench oxygen radicals. These 
phenotypic effects can be linked to several important metabolic 
outcomes of PC suppression in the lung adenocarcinoma A549 
cell line cultured in vitro and in vivo, including reduced lipid and 
nucleotide biosynthesis and altered glutathione homeostasis.
Results
PC expression and activity, but not glutaminase expression, are sig-
nificantly enhanced in early stages of malignant NSCLC tumors. PC 
protein expression was significantly higher in primary NSCLC 
tumors than in paired adjacent NC lung tissues (n = 86, P < 0.0001, 
Wilcoxon test) (Figure 1, B and C). The median PC expression was 
7-fold higher in the tumor, and the most probable (modal) overex-
pression in the tumor was approximately 3-fold higher (see Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI72873DS1). We found that PC expression 
was also higher in the tumor tissue compared with that detected 
in the NC tissue in 82 of 86 patients. In contrast, GLS1 expression 
was not significantly different between the tumor and NC tissues 
(P = 0.213, Wilcoxon test) (Figure 1C and Supplemental Table 1).
To estimate in vivo PC activity, the production of 13C3-Asp from 
13C6-glucose (Figure 1A) infused into NSCLC patients was deter-
mined by gas chromatography–mass spectrometry (GC-MS). A 
bolus injection of 10 g 13C6-glucose in 50 ml saline led to an aver-
age of 44% 13C enrichment in the plasma glucose immediately 
after infusion (Supplemental Table 2). Because the labeled glucose 
was absorbed by various tissues over the approximately 2.5 hours 
between infusion and tumor resection, plasma glucose enrichment 
dropped to 17% (Supplemental Table 2). The labeled glucose in both 
CA and NC lung tissues was metabolized to labeled lactate, but this 
occurred to a much greater extent in the CA tissues (Supplemental 
Figure 1A), which indicates accelerated glycolysis in these tissues.
The enrichment of 13C3-Asp (a PC marker, Figure 1A) was on 
average 117% higher (n = 34, P < 0.005) in NSCLC tumors than 
in NC lung tissue (Figure 1D). 13C3-Asp can also be produced after 
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tumors compared with levels in the paired 
NC lung tissue, which was also evident in 
5 other pairs of samples (data not shown) 
and is consistent with the Western blot data 
(Figure 1C). Moreover, PC was localized 
in the perinuclear region of the cancer-
ous epithelial cells but not in stromal cells 
in the tumor tissue (Figure 3, bottom left 
panel, and Supplemental Figure 3D). Such 
a perinuclear staining pattern is consistent 
with the localization of PC in the mitochon-
dria, which is supported by the perinuclear 
costaining of PC and the mitochondrial marker in NSCLC A549 
cells (Supplemental Figure 3, C and D).
In contrast, in the NC lung tissue, only macrophages were 
enriched in PC, while PC in other cell types stained weakly or 
was absent (Figure 3 and Supplemental Figure 3). Thus, PC is 
preferentially localized in the cancer cells of heterogeneous 
lung tumor tissues.
PC suppression by shRNA in lung cancer cells leads to growth arrest 
and decreased tumor burden in vivo. In order to assess the role of PC 
in the survival and growth of lung cancer cells, we used PC-specific 
shRNA to suppress PC mRNA expression in human A549 adenocar-
cinoma cells. As shown in Supplemental Figure 4A, vector shPC54 
reduced PC protein levels to 20% of the control levels, whereas PC 
expression was barely detected in cells transduced with shPC55. 
To verify the inhibition of PC activity in cells, we incubated empty 
vector– (shEV), shPC54-, and shPC55-transduced A549 cells in 
13C6-glucose for 24 hours and measured the markers for PC activity 
by GC-MS (Figure 1A). The levels of 13C3-citrate, 13C3-aspartate, and 
13C3-malate were reduced by both constructs; however, shPC55 was 
minase (see below). In addition, the 13C4-isotopologs of succinate, 
fumarate, malate (data not shown), and citrate (Supplemental 
Figure 2C) were detected, which confirms glutaminase action. 
However, the enrichment patterns of all but 1 isotopolog of the 
Krebs cycle intermediates derived from 13C5,15N2-glutamine were 
comparable between CA and NC tissues (Supplemental Figure 
2C). These data, along with the GLS1 expression data (Figure 1C), 
indicate that GLS1 is active and likely a significant player in the 
anaplerosis of the Krebs cycle in both types of tissues. But unlike 
PC, GLS1 was not significantly activated in NSCLC tumors rela-
tive to that seen in NC lung tissues.
PC is localized in the cancer cells within NSCLC tumors. 
NSCLC tumors are very heterogeneous and comprise various 
cell types including cancerous epithelial cells, pneumocytes, 
fibroblasts, endothelial cells, and immune cells such as macro-
phages. To determine whether PC is expressed specifically in 
cancer cells, we performed immunohistochemical analysis of 
paired CA and NC tissues from 9 patient samples. Figure 3 and 
Supplemental Figure 3 illustrate elevated PC levels in 4 NSCLC 
Figure 1. PC is activated in human NSCLC tumors. 
(A) PC and GLS1 catalyze the major anaplerotic 
inputs (blue) into the Krebs cycle to support the 
anabolic demand for biosynthesis (green). Also 
shown is the fate of 13C from 13C6-glucose through 
glycolysis and into the Krebs cycle via PC (red). 
(B) Representative Western blots of PC and GLS1 
protein expression levels in human NC lung (N) 
and NSCLC (C) tissues. (C) Pairwise PC and GLS1 
expression (n = 86) was normalized to α-tubulin 
and plotted as the log10 ratio of CA/NC tissues. For 
PC, nearly all log ratios were positive (82 of 86), 
with a clustering in the 0.5–1 range (i.e., typically 
3- to 10-fold higher expression in the tumor tis-
sue; Wilcoxon test, P < 0.0001). In contrast, GLS1 
expression was nearly evenly distributed between 
positive and negative log10 ratios and showed no 
statistically significant difference between the 
CA and NC tissues (Wilcoxon test, P = 0.213). Hor-
izontal bar represents the median. (D) In vivo PC 
activity was enhanced in CA tissue compared with 
that in paired NC lung tissues (n = 34) resected 
from the same human patients given 13C6-glucose 
2.5–3 hours before tumor resection. PC activity 
was inferred from the enrichment of 13C3-citrate 
(Cit+3), 13C5-Cit (Cit+5), 
13C3-malate (Mal+3), and 
13C3-aspartate (Asp+3) as determined by GC-MS. 
*P < 0.05 and **P < 0.01 by paired Student t test. 
Error bars represent the SEM.
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the net growth of all cell lines tested 
(Figure 4A). HCC827 and PC9 cells 
were more sensitive to PC knock-
down than were A549, H2030, or 
H1299 cells. HCC827 and PC9 cells 
also expressed more PC than did 
A549 and H1299 (Supplemental 
Figure 5A). The colony-formation 
assay revealed that PC knockdown 
significantly inhibited the ability of 
A549 and PC9 cells to form colonies 
in soft agar (Figure 4B). Although 
PC suppression did not reduce the 
total number of colonies produced 
by H1299 cells (Figure 4B), it dra-
matically affected the size of each 
colony (Supplemental Figure 5B), 
which is consistent with slower cell 
growth (Figure 4A). Moreover, PC-
suppressed cells became large and 
multinucleated, and the degree of 
multinucleation increased over time 
(Supplemental Figure 6, A–C).
We then determined whether 
PC-suppressed A549 cells are 
compromised in tumor growth in 
immune-deficient mice. We fol-
lowed the rate of tumor growth after 
injecting NSG mice with A549 cells 
transduced with an empty vector 
(shEV) or shPC55 (shPC). PC knock-
down resulted in a 2-fold slower 
rate of tumor growth (P = 0.001), as 
assessed by quadratic curve fitting 
of the tumor growth kinetics (Figure 
4C and Supplemental Table 3). We 
found that decreased tumor growth 
was clear by day 14 (P = 0.009). In 
addition, endpoint analysis of tumor 
weights showed a 30% smaller 
tumor in the shPC55 xenografts com-
pared with that observed in the shEV 
xenografts (P = 0.0073). However, 
the knockdown did not remain as 
effective in vivo as in cell culture. We found that PC expression in 
the knockdown tumors after 36 days had increased to 30% to 60% 
of that in tumors with control empty vector (Supplemental Figure 
7A). Interestingly, the growth rate of individual tumors correlated 
significantly (P = 0.006) with their level of PC expression (Figure 
4D). Therefore, residual PC expression is likely to account for the 
limited ability of the shPC55 tumors to grow. Altogether, these data 
indicate that PC expression is important for in vivo tumor growth.
PC knockdown perturbs Krebs cycle activity, the anabolic capacity 
of the cell, and glutathione homeostasis. To investigate the metabolic 
consequences of PC knockdown, A549 cells were transduced with 
shPC55, grown in 13C6-glucose or 13C5,15N2-glutamine, and incorpo-
ration of the label was analyzed by NMR and MS. In addition, the 
more effective than shPC54 (Supplemental Figure 4B). It is interest-
ing to note that increased PC activity may occur in other unrelated 
transformed cell lines (3, 27). PC knockdown slowed cell growth, 
again with shPC55 being more effective than shPC54 (Supplemental 
Figure 4C). This corroborates the greater extent of PC knockdown 
by shPC55 (Supplemental Figure 4A). Furthermore, PC knockdown 
greatly decreased the number of colonies formed in soft agar (Sup-
plemental Figure 4D), reduced cell viability (Supplemental Figure 
4E), and altered morphology (Supplemental Figure 4F).
Since shPC55 was the more effective construct in suppressing 
both PC expression and activity, we used it to probe the effects of 
PC suppression on the additional NSCLC adenocarcinoma cell 
lines H1299, H2030, HCC827, and PC9. PC knockdown inhibited 
Figure 2. Ex vivo CA lung tissue slices have enhanced oxidation of glucose through glycolysis and the 
Krebs cycle with and without PC input compared with that of paired NC lung slices. Thin slices of CA 
and NC lung tissues freshly resected from 13 human NSCLC patients were incubated with 13C6-glucose 
for 24 hours as described in the Methods. The percentage of enrichment of lactate, citrate, glutamate, 
and aspartate was determined by GC-MS. (A) 1H{13C} HSQC NMR showed an increase in labeled lactate, 
glutamate, and aspartate. In addition, CA tissues had elevated 13C abundance in the ribose moiety of the 
adenine-containing nucleotides (1′-AXP), indicating that the tissues were viable and had enhanced capac-
ity for nucleotide synthesis. (B) CA tissue slices (n = 13) showed increased glucose metabolism through gly-
colysis based on the increased percentage of enrichment of 13C3-lactate (“3”), and through the Krebs cycle 
based on the increased percentage of enrichment of 13C4–6-citrate (“4–6”) and 
13C3–5-glutamate (“3–5”) (see 
13C fate tracing in C). *P < 0.05 and **P < 0.01 by paired Student’s t test. Error bars represent the SEM. (C) 
An atom-resolved map illustrates how PC, PDH, and 2 turns of the Krebs cycle activity produced the 13C iso-
topologs of citrate and glutamate in B, whose enrichment were significantly enhanced in CA tissue slices.
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ciency in NSCLC cells. shPC55- or shEV-transduced A549 
cells were incubated with 13C5,15N2-glutamine to track gluta-
minolysis. As shown in Figure 5B, GLS1 activity can produce 
13C5,15N1-glutamate (6) from 13C5,15N2-glutamine (7), which 
subsequently enters the Krebs cycle to generate 13C4-succinate 
(4), 13C4- (4) or 13C4,15N1-aspartate (5), and 13C4-citrate (4). A549 
cells readily took up and metabolized 13C5,15N2-glutamine 
into these labeled metabolites. However, the levels of all 
these labeled isotopologs were significantly reduced in the 
PC-knockdown cells (highlighted by red circles in Figure 5B), 
which is consistent with reduced GLS activity. Decreased 
GLS activity was also evident in the 1H-{13C} HSQC spec-
tra, which showed that PC-suppressed cells incorporated 
less glutamine carbon into glutamate, aspartate, and citrate 
(Supplemental Figure 9B). It should be noted that amido-
transferase activity can also contribute to the production of 
the labeled products shown in Figure 5B and Supplemental 
Figure 9B. However, changes in amidotransferase activity 
are unlikely to account for the observed blockage of Gln 
metabolism induced by PC knockdown. This is because 
PC knockdown in A549 cells or in mouse xenografts led to 
suppressed GLS1 expression (Supplemental Figure 10A). 
In addition, A549 cells exhibited high GLS1 expression and 
GLS activity in cell lysates, suggesting that GLS1 expression 
is important for A549 cell growth (see below).
To further probe the importance of glutamine utiliza-
tion in PC-suppressed cells, A549 cells were incubated with 
either 2 or 0.2 mM glutamine. We found that glutamine restriction 
significantly reduced the growth rate of control cells by approxi-
mately 30%, but had no influence on PC-knockdown cells (Sup-
plemental Figure 10, B and C). Thus, glutaminolysis does not com-
pensate for the loss of PC as an anaplerotic supplier of precursors 
to the Krebs cycle intermediates in NSCLC cells.
Beyond supplying reducing equivalents and energy (ATP 
and GTP), the Krebs cycle also supplies various precursors for 
anabolism. For instance, citrate is exported from the mitochon-
dria to supply acetyl CoA for fatty acid synthesis; OAA is transam-
inated to aspartate for pyrimidine biosynthesis; α-ketoglutarate 
is aminated to glutamate for de novo glutathione synthesis; and 
malate is decarboxylated to pyruvate, providing NADPH for lipid 
biosynthesis and glutathione reduction (Figure 1A). To determine 
how perturbation of the Krebs cycle by PC suppression affects 
these anabolic pathways, we used SIRM to follow the biosynthe-
sis of nucleotides, lipids, and glutathione in A549 cells grown in 
13C6-glucose or 13C5-glutamine tracers.
PC knockdown reduced the levels of uracil and adenine 
nucleotides both in cell culture and in vivo (Supplemental Fig-
ure 11, A and B). These changes were at least in part attributed to 
attenuated biosynthesis of these nucleotides by PC knockdown, 
as evidenced by the reduced incorporation of labeled glucose 
into the C1′ ribose carbon observed in HSQC NMR analysis of 
1H{13C} (Supplemental Figure 9A and Supplemental Figure 11A). 
This can be accounted for by the reduced production of the ura-
cil and cytosine ring via decreased synthesis of their precursor 
aspartate from glucose and glutamine both in cells (Figure 5) and 
in vivo (Supplemental Figure 8). Consistently, we observed less 
incorporation of the glucose and glutamine carbon into the ring 
mice engrafted with shPC55- or shEV-transduced A549 cells were 
injected with 13C6-glucose. With the glucose tracer, we found no evi-
dence that PC affects aerobic glycolysis, as PC-knockdown cells had 
similar glucose consumption and production of total and labeled 
lactate in the media (Supplemental Figure 7B). In addition, the lac-
tate released into the media had the same percentage of enrichment 
pattern in PC-knockdown and control cells (Supplemental Figure 
7C). Likewise, mouse tumors bearing shEV or shPC55 had compa-
rable concentrations of total lactate, labeled lactate derived from 
13C6-glucose (Supplemental Figure 7D), and percentage of lactate 
enrichment patterns (Supplemental Figure 7E).
In contrast, PC knockdown reduced the oxidation of 
13C6-glucose through the Krebs cycle. As expected, entry of gly-
colytic 13C3-pyruvate into the Krebs cycle via PC was inhibited, as 
indicated by the reduced production of various 13C3 isotopologs and 
13C5-citrate (highlighted by blue circles in Figure 5A). Interestingly, 
pyruvate entry via PDH was also hindered by PC knockdown (high-
lighted by red circles in Figure 5A). We observed the same trend in 
mouse tumors initiated by PC-knockdown cells (Supplemental Fig-
ure 8), although the effects were less severe than those seen in cell 
cultures. This is again consistent with the finding that A549 cells 
with PC knockdown were able to recover PC expression to some 
extent in vivo (Supplemental Figure 7A). Reduced glucose oxida-
tion through the Krebs cycle in cells and tumors was also observed 
by 1H-{13C} heteronuclear single-quantum coherence (HSQC) 
NMR (Supplemental Figure 9, A and C), which showed reduced 
incorporation of 13C from the glucose tracer into citrate, aspartate, 
glutamate, and the glutamate residue of glutathione.
Since glutaminolysis is another major anaplerotic pathway, 
we asked whether this pathway could compensate for PC defi-
Figure 3. Immunohistochemical localization of PC in lung tissues. Pairs of 
CA and NC tissues obtained from NSCLC patients were stained with anti-PC 
antibody. Shown are representative pairs of micrographs from 1 patient. Original 
magnification, ×400 (top panels) and ×600 (bottom panels). Additional patient 
data are provided in Supplemental Figure 3. In CA tissues, viable cancer cells 
stained intensely for PC, while macrophages stained weakly, and other stromal 
cells showed no staining for PC. In adjacent NC tissues, macrophages stained 
strongly for PC, while pneumocytes stained very weakly for the protein.
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of UTP and CTP by Fourier transform ion cyclotron resonance 
(FT-ICR-MS) analysis (Figure 6A).
Lipid biosynthesis was assessed in the nonpolar fractions of the 
same cell extracts by FT-ICR-MS, which can resolve a large number 
of intact lipids and determine their 13C enrichments in the glycerol 
and fatty acyl components (28). PC knockdown greatly inhibited 
synthesis of the major cell membrane components phosphatid-
ylcholines from both glucose and glutamine tracers (Figure 6B). 
Using 13C6-glucose as a tracer, 13C was incorporated extensively into 
the glycerol backbone (3 13C atoms), fatty acyl chains (even 13C), and 
glycerol plus fatty acyl residues (odd >3 13C) in shEV control cells 
(28). With PC suppression, almost all phosphatidylcholine species 
were either unlabeled (as 0) or labeled at the glycerol backbone 
only (as 3), while the 13C isotopologs reflecting fatty acyl synthesis 
from glucose (even and odd >3) were greatly diminished in A549 
cells. In addition, the glycerol backbone precursor α-glycerol-3-
phosphate (αG3P) (such as 13C3-αG3P derived from 13C6-glucose) 
accumulated in the PC-knockdown cells (Figure 
6B). Likewise, fatty acyl synthesis from 13C5-glu-
tamine (“Even” in Figure 6B) via glutaminoly-
sis and the Krebs cycle was greatly attenuated 
in PC-suppressed cells. Taken together, these 
results suggest that PC knockdown severely 
inhibits lipid production by blocking the biosyn-
thesis of fatty acyl components but not the glu-
cose-derived glycerol backbone. This is consis-
tent with decreased Krebs cycle activity (Figure 
5), which in turn curtails citrate export from the 
mitochondria to supply the fatty acid precursor 
acetyl CoA in the cytoplasm.
Finally, de novo glutathione synthesis was 
analyzed by 1H{13C} HSQC NMR. Glutathione 
synthesis from both glucose and glutamine 
was suppressed by PC knockdown (Supple-
mental Figure 9, A and B). Reduced de novo 
synthesis led to a large decrease in the total 
level of reduced glutathione (GSH; Supple-
mental Figure 12, A and B). At the same time, 
PC-knockdown cells accumulated slightly 
more oxidized GSH (GSSG; Supplemental 
Figure 12, A and B), leading to a significantly 
reduced GSH/GSSG ratio both in cell culture 
and in vivo (Supplemental Figure 12C). To 
determine whether this perturbation of gluta-
thione homeostasis compromises the ability of 
PC-suppressed cells to handle oxidative stress, 
we measured ROS production by DCFDA fluo-
rescence. PC-knockdown cells had over 70% 
more basal ROS than did control cells (0 mM 
H2O2; Supplemental Figure 12D). When cells 
were exposed to increasing concentrations of 
H2O2, the knockdown cells were less able to 
quench ROS, as they produced up to 300% 
more ROS than did control cells (Supplemen-
tal Figure 12D). However, N-acetylcysteine 
(NAC) at 10 mM did not rescue the growth of 
PC-knockdown cells, suggesting that such a 
growth effect is not simply related to an inability to regenerate 
GSH from GSSG. Altogether, these results show that PC suppres-
sion compromises anaplerotic input into the Krebs cycle, which 
in turn reduces the activity of the Krebs cycle, while limiting the 
ability of A549 cells to synthesize nucleotides, lipids, and gluta-
thione. These downstream effects of PC knockdown were also 
evident when comparing the metabolism of shPC55-transduced 
A549 cells against that of A549 cells transduced with a scram-
bled vector (shScr) (Supplemental Figure 13), which suggests 
that they are on-target effects of PC knockdown.
Glutaminolysis is also a functionally significant source of anaple-
rosis in NSCLC. To determine whether GLS1 is functionally impor-
tant for NSCLC cells, we suppressed GLS1 expression by shRNA 
in both A549 and H1299, which resulted in reduced growth rates 
in both cells (Supplemental Figure 14, A and B). The growth of 
A549, H1299, and PC9 cells also decreased in response to BPTES 
(a known GLS inhibitor) treatment (Supplemental Figure 14C). 
Figure 4. PC suppression via shRNA inhibits proliferation and tumorigenicity of human 
NSCLC cell lines in vitro and in vivo. Proliferation and colony-formation assays were initiated 
1 week after transduction and selection with puromycin. A549 xenograft in NSG mice was per-
formed 8 days after transduction. *P < 0.01, **P < 0.001, ***P < 0.0001, and ****P < 0.00001 
by Student t test, assuming unequal variances. Error bars represent the SEM. (A) NSCLC cells 
lines were transduced with shPC55 or shEV. Proliferation assays (n = 6) revealed substantial 
growth inhibition induced by PC knockdown in all 5 cell lines after a relatively long latency 
period. (B) Colony-formation assays indicated that PC knockdown reduced the capacity of A549 
and PC9 cells to form colonies in soft agar (n = 3). (C) Tumor xenografts from shPC55-transduced 
A549 cells showed a 2-fold slower growth rate than did control shEV tumors (P < 0.001 by the 
unpaired Welch version of the t test). Tumor size was calculated as πab/4, where a and b are 
the x,y diameters. Each point represents an average of 6 mice. The solid lines are the nonlinear 
regression fits to the equation: size = a + bt2, as described in the Methods. (D) The extent of 
PC knockdown in the mouse xenografts (n = 6) was lesser than that in cell cultures, leading to 
less attenuation of PC expression (30%–60% of control) and growth inhibition. In addition, PC 
expression in the excised tumors correlated with the individual growth rates, as determined by 
Pearson’s correlation coefficient.
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Further, 13C isotopolog analysis of these 3 cell lines after incuba-
tion with 13C5,15N2-Gln showed that they used glutamine as a sig-
nificant source of carbon for the Krebs cycle (Supplemental Figure 
14D). Therefore, it appears that both GLS1 and PC are important 
for supporting proliferation and Krebs cycle activity in NSCLC 
cells. 13C5,15N2-Gln as a substantial carbon source for the Krebs 
cycle was also recapitulated in the human tissue slice data (Supple-
mental Figure 2C). However, unlike PC-based anaplerosis (Figure 
2B), GLS-fueled anaplerotic activity was comparable between CA 
and NC tissue slices (Supplemental Figure 2C), which is consistent 
with the lack of discernible distinction in GLS1 protein expression 
between bulk CA and NC tissues (Figure 1C).
Figure 5. PC knockdown perturbs glucose and glutamine flux through the Krebs cycle. 13C Isotopolog concentrations were determined by GC-MS (n = 3). 
Values represent the averages of triplicates, with standard errors. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Student’s t test, assuming 
unequal variances. The experiments were repeated 3 times. (A) A549 cells were transduced with shPC55 for 10 days before incubation with 13C6-glucose 
for 24 hours. As expected, the 13C isotopologs of Krebs cycle metabolites produced via PC and Krebs cycle activity were depleted in PC-deficient cells 
(tracked by blue dots in the atom-resolved map and blue circles in the bar graphs; see also Figure 2C). In addition, 13C6-glucose metabolism via PDH was 
also perturbed (indicated by red dots and circles). (B) Treatment of PC-knockdown cells with 13C5,15N2-glutamine revealed that anaplerotic input via GLS 
did not compensate for the loss of PC activity, since GLS activity was attenuated, as inferred from the activity markers (indicated by red dots and circles). 
Decarboxylation of glutamine-derived malate by malic enzyme (ME) and reentry of glutamine-derived pyruvate into the Krebs cycle via PC or PDH (shown 
in blue and green, respectively) were also attenuated. Purple diamonds denote 15N; black diamonds denote 14N.
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Figure 6. PC suppression hinders Krebs cycle–fueled biosynthesis. (A) 13C atom–resolved pyrimidine biosynthesis from 13C6-glucose and 13C5-glutamine 
is depicted with a 13C5-ribose moiety (red dots) produced via the pentose phosphate pathway (PPP) and 
13C1-3  uracil ring (blue dots) derived from  
13C2-4-aspartate produced via the Krebs cycle or the combined action of ME and PC (blue dots). A549 cells transduced with shPC55 or shEV were incu-
bated with 13C6-glucose or 
13C5-glutamine for 24 hours. Fractional enrichment of UTP and CTP isotopologs from FT-ICR-MS analysis of polar cell extracts 
showed reduced enrichment of 13C6-glucose–derived 
13C5-ribose (the “5” isotopolog) and 
13C6-glucose– or 
13C5-glutamine–derived 
13C1-3-pyrimidine rings 
(the “6–8” or “1–3” isotopologs, highlighted by dashed green rectangles; for the “6–8” isotopologs, 5 13Cs arose from ribose and 1–3 13Cs from the ring) 
(10, 45). These data suggest that PC knockdown inhibits de novo pyrimidine biosynthesis from both glucose and glutamine. (B) Glucose and glutamine 
carbons enter fatty acids via citrate. FT-ICR-MS analysis of labeled lipids from the nonpolar cell extracts showed that PC knockdown severely inhibited 
the incorporation of glucose and glutamine carbons into the fatty acyl chains (even) and fatty acyl chains plus glycerol backbone (odd >3) of phosphat-
idylcholine lipids. However, synthesis of the 13C3-glycerol backbone (the “3” isotopolog) or its precursor 
13C3-α-glycerol-3-phosphate (αG3P, m+3) from 
13C6-glucose was enhanced rather than inhibited by PC knockdown. These data suggest that PC suppression specifically hinders fatty acid synthesis 
in A549 cells. Values represent the averages of triplicates (n = 3), with standard errors. *P < 0.05, **P < 0.01,  and ***P < 0.001 by Student’s t test, 
assuming unequal variances.
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cells, thus accounting for the failure of NAC to rescue PC-suppressed 
cells from growth inhibition (Supplemental Figure 12E).
Although active, anaplerotic glutaminolysis could not com-
pensate for lost PC-based anaplerosis in A549 cells (Figure 5B and 
Supplemental Figure 10), despite the abundant supply of glutamine. 
This is presumably due to the reduced expression of GLS1 in PC-
knockdown cells or in xenograft tumors (Supplemental Figure 10A). 
Moreover, we noted that in the human NSCLC tumors, in which PC 
was underexpressed, GLS1 was also underexpressed. These results 
suggest that PC and GLS1 are not compensatory in their functions in 
human NSCLC, in contrast to some glioma cells (20).
Finally, the improved variant of Warburg’s tissue slices (25) 
that we have introduced enables detailed ex vivo analysis of 
patient-specific tumor metabolism (Figure 2 and Supplemental 
Figure 2), while maintaining most of the tissue microenviron-
ment and cellular heterogeneity without systemic complications 
from the blood supply. This ex vivo system also affords versatil-
ity of experimental manipulations (e.g., tracer choices or drug 
treatments) similar to that of the pure cell culture system. In our 
case, enhanced in vivo PC activity (Figure 1D) in human NSCLC 
tumor tissues was confirmed by the corresponding ex vivo tracer 
studies (Figure 2B). Equally important is that the ex vivo system 
enables unequivocal determination of anaplerotic glutaminoly-
sis using the labeled glutamine tracer (Supplemental Figure 2C), 
thereby corroborating the lack of in vivo upregulation of GLS1 in 
human tumor tissues (Figure 1C). This would have been difficult to 
demonstrate in vivo in human patients due to cost considerations. 
Thus, the ex vivo tissue culture system can complement existing 
model systems for translating bench-to-bedside understanding, 
particularly in an individualized manner (26).
In conclusion, our results in primary human lung tumors and ex 
vivo tissue slices show that PC protein expression and activity are 
enhanced in early stages of human NSCLC tumor tissues compared 
with that seen in NC tissues from the same patient and that the PC 
protein is localized in the cancer cells within the tumor tissue. Silenc-
ing PC expression and activity compromises NSCLC cell growth, 
tumorigenicity, and antioxidation capacity. These phenotypic effects 
of PC suppression were related to the vital metabolic functions of PC 
in NSCLC, including sustaining mitochondrial Krebs cycle activity, 
nucleotide and lipid biosynthesis, and redox homeostasis.
Methods
Patient accrual. Eighty-six patients with suspected primary lung can-
cer but without diagnosed diabetes were recruited on the basis of 
their surgical eligibility. The patients were then randomly grouped 
into 2 arms. In the first arm, the patients were overnight fasted 
(>8 hours) before 10 grams of uniformly labeled 13C glucose was 
administered i.v. and again 2.8 ± 0.5 hours prior to video-assisted 
thorascopic surgical (VATS) wedge resection, as previously described 
in detail (35), to enable tracking of metabolic pathways (21, 36–38). 
Patients in the second arm did not receive a glucose injection. We 
and others have previously discussed the relative advantages of bolus 
injections versus slow-infusion protocols (21, 36–41). The bolus injec-
tion leads to an initially high blood glucose concentration, which then 
decays to the baseline level, thus limiting the length of time that effec-
tive labeling can be achieved but more closely approximating an ini-
tial rate condition. In comparison, a prolonged slow infusion can lead 
Discussion
Prior to our earlier report (21), the upregulation of PC in NSCLC 
was an undocumented phenomenon. Most research on anaplerosis 
in cancer cells has focused on the upregulation of glutamine metab-
olism via GLS1 in established cell lines, which cannot recapitulate 
the influence of the tumor microenvironment (17, 29–32). To gain 
insights into metabolic reprogramming in human cancer, it is imper-
ative to study human tumors in situ and to compare paired CA and 
surrounding NC tissues from the same patient to circumvent cell 
culture artifacts, while eliminating confounding intrinsic genetic 
and physiological variables. It is also important to implement a fast 
and consistent liquid N2–quenching protocol to minimize metabolic 
artifacts during tissue sampling after surgical resection.
By addressing the two aspects of our study, we found that 
although PC expression and activity in lung tissues varied sub-
stantially from patient to patient, 94% of the NSCLC tumors (82 
of 86) overexpressed PC, and 73% (25 of 34) showed elevated PC 
activity in vivo relative to that in their paired NC lung tissues. This 
contrasts with the insignificant difference observed in the expres-
sion of GLS1 between CA and NC tissues (Figure 1C). PC was 
highly expressed exclusively in cancer cells of early-stage NSCLC 
tumor tissues. In contrast, PC was not expressed in the pneumo-
cytes, but its expression was evident in macrophages of paired NC 
tissue (Figure 3 and Supplemental Figure 3). We surmise that the 
latter may be related to inflammation, which is common in the 
lungs of NSCLC patients.
The requirement of PC for NSCLC proliferation and tum-
origenesis was demonstrated by PC suppression in several lung 
cancer cell lines (Figure 4, A and B) and in vivo for A549 cells (Fig-
ure 4, C and D) using specific shRNAs. The long latency period 
between mRNA knockdown and phenotypic effects (Figure 4A) 
may be related to the long half-life of PC (1–2 d, ref. 33). The intra-
cellular level of PC may need several cell divisions to be attenuated 
sufficiently to compromise anaplerosis, leading to reduced cell pro-
liferation. We have verified that inhibition of cell proliferation by 
PC suppression is accompanied by a decrease in anaplerotic input 
into the Krebs cycle (Figure 5) and the consequent reduction of 
nucleotide (Figure 6A, Supplemental Figure 11A, and Supplemen-
tal Figure 13C) and lipid biosynthesis (Figure 6B and Supplemen-
tal Figure 13D). The correlation of the severity of these metabolic 
effects with the efficiency of the knockdown and the inhibition of 
cell proliferation both in vitro and in vivo (Figure 4 and Supplemen-
tal Figure 4) is consistent with PC knockdown being a significant 
contributor to the reduced proliferation. Although we have clearly 
demonstrated the importance of PC for cancer cell proliferation 
and that enzymic activity is an important aspect of the role of PC, 
we cannot rule out the possibility that the protein has alternative 
nonenzymic functions in the cells, as has been observed for several 
other metabolic enzymes (34).
In addition, PC knockdown in A549 cells greatly depletes the 
GSH pool and perturbs glutathione homeostasis (Supplemental Fig-
ure 12C) by blocking de novo glutathione synthesis (Supplemental 
Figure 12B and Supplemental Figure 13B), which presumably leads 
to greater ROS production (Supplemental Figure 12D) and a compro-
mised ability to survive oxidative stress. Exogenous reductants such 
as NAC in some circumstances can reduce cellular GSSG to GSH, 
but NAC cannot overcome the depleted GSH pool in PC-suppressed 
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100 μl 1.075 M [U-13C]-glucose 3 times at 15-minute intervals. Blood 
samples were taken intraorbitally immediately after the first injection 
and at sacrifice 60 minutes later. The tumors were immediately excised 
and weighed prior to flash-freezing in liquid N2. Metabolites were 
extracted as described above (43).
Tracer studies in ex vivo tissue slices. These experiments were per-
formed on fresh slices of paired tumor and nontumorous lung tissues 
resected from individual patients (26). Upon lung resection, thin 
slices (0.5–1 mm thick) of tissue were excised using a Weck micro-
tome in the operating room. These slices were immediately placed 
in T-flasks containing DMEM with the appropriate tracer (either 
10 mM [U-13C]-glucose or 2 mM [U-13C,15N]-glutamine), and then 
transferred to a CO2 incubator set at 37°C and 5% CO2. The flasks 
were continuously rocked for 24 hours for aeration and to maintain 
constant nutrient supplies at the tissue surface, while avoiding local 
buildup of waste products such as acids. The slices were then washed 
in cold PBS, frozen in liquid N2, pulverized as described above, 
and extracted for polar and nonpolar metabolites and proteins as 
described above for cell cultures.
SIRM analysis. Polar metabolite fractions from cells, patient tissues, 
and mouse tumors were analyzed by GC-MS, NMR, and FT-ICR-MS 
as previously described (10, 42). Nonpolar fractions were analyzed 
for lipids by FT-ICR-MS as previously described (10, 28). 13C frac-
tional enrichments were calculated for metabolite isotopomers 
(13C at different atomic positions) and isotopologs (different num-
bers of 13C atoms) as the level of a given isotopomer or isotopolog 
divided by the summed level of all isotopomers or isotopologs. The 
absolute levels of labeled metabolites were obtained by normalizing 
the moles of metabolites to the extractable protein content.
Statistics. Statistical analyses were conducted using SPSS 19.0 
(IBM- Somers) and Kaleidagraph (Synergy Software). Differences 
between patient cohorts were assessed using the paired Wilcoxon 
test, the 2-tailed Student t test on the logarithms of the values 
(i.e., for fractional differences), and by examining the distribution 
terms of the mean, median, and modal values. The expression ratios 
(CA/NC) for PC or GLS were highly non-normally distributed, and 
the mean, median, and modal values were calculated accordingly. The 
modal values were estimated from the maximum in the frequency- 
versus-ratio histograms and were thus slightly affected by the bin size.
Mouse tumor sizes were tested using an unpaired Welch’s ver-
sion of the t test (44). First, the significance was evaluated at each 
time point after injection. Second, all growth curves were fitted 
to different models, including exponential, power, and quadratic 
growth, and best-fit parameters with the associated standard devi-
ations were subjected to Welch’s t test. The simplest form that gave 
good fitting statistics was a simple quadratic equation: size = a + bt2. 
In this form, a is the initial tumor size at t = 0, and b is the specific 
growth rate. Third, the tumor weights at necropsy were compared 
as 2 groups. The significance of differences between shEV and shPC 
groups in terms of proliferation and metabolites was determined 
using Welch’s t test. In all analyses, a P value of less than 0.05 was 
considered significant.
Study approval. This study was approved by the IRB of the Uni-
versity of Louisville. Written informed consent was obtained from all 
subjects prior to inclusion in this study. The murine tumor protocol was 
performed in compliance with all relevant laws and institutional guide-
lines and was approved by the IACUC of the University of Louisville.
to a higher degree of isotopic labeling and approach isotopic steady-
state conditions, but is a much more involved process, and a true iso-
topic steady state may be difficult and cost prohibitive to achieve.
The extent of resection was determined by the surgeon accord-
ing to clinical criteria. The majority of the specimens were obtained 
from wedge resections to minimize surgical times, while the remain-
der were acquired in less than 5 minutes after the pulmonary vein 
was clamped; both practices helped avoid development of significant 
ischemia in resected tissues. Immediately after resection, the tumor 
was transected, and sections of CA tissue and surrounding NC lung 
tissue at least 2 cm away from the tumor were biochemically quenched 
by flash-freezing in liquid N2 (36, 38). The margins of the tumor were 
initially assessed by the surgeon by visual inspection. Parallel tissue 
samples were sent to on-site pathologists for confirmation of the diag-
nosis and the cancer-free margins. The remaining specimen was pre-
served in buffered formalin for detailed pathological examination.
Sample preparation. The frozen tissue samples were pulverized 
to a particle size of less than 10 μm in liquid N2 using a Spex freezer 
mill (Spex). Polar and nonpolar metabolites were extracted from the 
ground tissue, which also yielded insoluble protein residues (21, 42). 
The protein residues were extracted by homogenization in 2% SDS, 
62.5 mM Tris, and 1 mM DTT buffer for protein determination using 
the Pierce BCA method (Thermo Fisher Scientific).
Electrophoresis, Western blotting, immunohistochemistry, cell prolif-
eration, and colony-formation assays. Detailed protocols are described 
in the Supplemental Methods.
shRNA knockdown of PC in lung cancer cells. NSCLC cells lines 
and HEK 293T cells obtained from ATCC were grown in DMEM 
media containing 0.45% glucose and 4 mM glutamine at 37°C, 95% 
relative humidity, and 5% CO2. HEK 293T cells were transfected 
with pCMV and pMD2.G vectors carrying viral packaging (gag, pol, 
rev) and envelope (VSV-G) genes, along with a plasmid contain-
ing shRNA against PC (shPC54 or shPC55), shEV, or shScr (Mission 
shRNA; Sigma-Aldrich). The anti-PC sequences used were: shPC54: 
CCGGGCCCAGTTTATGGTGCAGAATCTCGAGATTCTGCAC-
CATAAACTGGGCTTTTTG; shPC55: CCGGGCCAAGGAGAA-
CAACGTAGATCTCGAGATCTACGTTGTTCTCCTTGGCTTTTTG.
After 48 hours, medium from the transfected cells was collected, 
filtered, supplemented with 16 μg/ml polybrene, and added to 
NSCLC cell lines in an equal volume of DMEM media. Fresh media 
were added to the 293T cells, and after 24 hours, transduction of 
the NSCLC cells was repeated. The resulting NSCLC cells bearing 
the plasmid with the puromycin resistance gene were selected using 
1 μg/ml puromycin.
Tracer studies in cell cultures. Cells transduced with shEV, shScr, 
shPC54, or shPC55 were incubated in DMEM in the presence of 10 
mM 13C6-glucose or 2 mM 13C5,15N2-glutamine for 24 hours, quenched 
in cold acetonitrile, and extracted in acetonitrile/water/chloroform 
(v/v 2:1.5:1), as described previously (10).
Tracer studies in mouse xenografts of PC-knockdown cells. To assess 
tumor growth of PC-knockdown A549 cells, 6-week-old female NOD/
SCID gamma (NSG) mice (n = 6 mice/group) (The Jackson Laboratory) 
were injected s.c. with 8 × 106 cells containing either shEV or shPC55 
mixed with Matrigel (BD Biosciences). The tumor diameters were 
determined 3 times per week by caliper. Tumor sizes were calculated 
as πab/4, where a and b are the lengths of the maximum and minimum 
dimensions. After 36 days, the mice were injected via the tail vein with 
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